Cadmium and arsenic-induced-stress differentially modulates Arabidopsis root architecture, peroxisome distribution, enzymatic activities and their nitric oxide content

In plant cells, cadmium (Cd) and arsenic (As) exert toxicity mainly by inducing oxidative stress through an imbalance between the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), and their detoxification. Nitric oxide (NO) is a RNS acting as signalling molecule coordinating plant development and stress responses, but also as oxidative stress inducer, depending on its cellular concentration. Peroxisomes are versatile organelles involved in plant metabolism and signalling, with a role in cellular redox balance thanks to their antioxidant enzymes, and their RNS (mainly NO) and ROS. This study analysed Cd or As effects on peroxisomes, and NO production and distribution in the root system, including primary root (PR) and lateral roots (LRs). Arabidopsis thaliana wild-type and transgenic plants enabling peroxisomes to be visualized in vivo, through the expression of the 35S-cyan fluorescent protein fused to the peroxisomal targeting signal1 (PTS1) were used. Peroxisomal enzymatic activities including the antioxidant catalase, the H2O2-generating glycolate oxidase, and the hydroxypyruvate reductase, and root system morphology were also evaluated under Cd/As exposure. Results showed that Cd and As differently modulate these activities, however, catalase activity was inhibited by both. Moreover, Arabidopsis root system was altered, with the pollutants differently affecting PR growth, but similarly enhancing LR formation. Only in the PR apex, and not in LR one, Cd more than As caused significant changes in peroxisome distribution, size, and in peroxisomal NO content. By contrast, neither pollutant caused significant changes in peroxisomes size and peroxisomal NO content in the LR apex

Nitric oxide alleviates cadmium- but not arsenic-induced damages in rice roots

Nitric oxide (NO) has signalling roles in plant stress responses. Cadmium (Cd) and arsenic (As) soil pollutants alter plant development, mainly the root-system, by increasing NO-content, triggering reactive oxygen species (ROS), and forming peroxynitrite by NO-reaction with the superoxide anion. Interactions of NO with ROS and peroxynitrite seem important for plant tolerance to heavy metal(oid)s, but the mechanisms underlying this process remain unclear. Our goal was to investigate NO-involvement in rice (Oryza sativa L.) root-system after exposure to Cd or As, to highlight possible differences in NO-behaviour between the two pollutants. To the aim, morpho-histological, chemical and epifluorescence analyses were carried out on roots of different origin in the root-system, under exposure to Cd or As, combined or not with sodium nitroprusside (SNP), a NO-donor compound. Results show that increased intracellular NO levels alleviate the root-system alterations induced by Cd, i.e., inhibition of adventitious root elongation and lateral root formation, increment in lignin deposition in the sclerenchyma/endodermis cell-walls, but, even if reducing As-induced endodermis lignification, do not recover the majority of the As-damages, i.e., enhancement of AR-elongation, reduction of LR-formation, anomalous tissue-proliferation. However, NO decreases both Cd and As uptake, without affecting the pollutants translocation-capability from roots to shoots. Moreover, NO reduces the Cd-induced, but not the As-induced, ROS levels by triggering peroxynitrite production. Altogether, results highlight a different behaviour of NO in modulating rice root-system response to the toxicity of the heavy metal Cd and the metalloid As, which depends by the NO-interaction with the specific pollutant

From asking to observing. Behavioural measures of socio-emotional and motivational skills in large-scale assessments

Socio-emotional and motivational skills are routinely measured using self-reports in large-scale educational assessments. Measures exploiting test-takers’ behaviour during the completion of questionnaires or cognitive tests are increasingly used as alternatives to self-reports in the economics of education literature. We compute behavioural measures of socio-emotional and motivational skills using data from the Programme for International Student Assessment (PISA). We find that these measures capture important aspects of students' academic profiles: some are importantly associated with contemporaneous performance and educational attainment and most measures have a high degree of stability over time. However, these measures are only limitedly correlated among themselves and have low correlations with self-report measures of the same constructs. This is likely a reflection of the fact that behavioural measures are representations of the test taker current ‘state’, rather than descriptions of the participant view of their own ‘trait’ like the self-report measures. Moreover, the low correlation across measures suggests that they capture different behavioural responses to the test-taking situation. These differences are still limitedly understood because the measures are constructed ex-post using collateral information collected during the administration of assessments rather than developed ex ante in line with theoretical models of human cognition and affect

Cadmium and arsenic affect root development in Oryza sativa L. negatively interacting with auxin

Cadmium (Cd) and arsenic (As), non essential, but toxic, elements for animals and plants are frequently present in paddy fields. Oryza sativa L., a staple food for at least the half of world population, easily absorbs As and Cd by the root, and in this organ the pollutants evoke consistent damages, reducing/modifying the root system. Auxins are key hormones in regulating all developmental processes, including root organogenesis. Moreover, plants respond to environmental stresses, such as those caused by Cd and As, by changing levels and distribution of endogenous phytohormones. Even though the effects of Cd and As on the roots have been investigated in some species, it remains necessary to deepen the knowledge about the cross-talk between these toxic elements and auxin during root formation and development, in particular in agronomically important plants, such as rice. Hence, the research goal was to investigate the interactions between Cd and As, alone or combined, and auxin during the development of rice roots. To reach the aim, morphological, histological and histochemical analyses were carried out on seedlings, exposed or not to Cd and/or As, belonging to the wild type and transgenic lines useful for monitoring indole-3-acetic acid (IAA) localization, i.e., OsDR5:GUS, and IAA cellular influx and efflux, i.e., OsAUX1:GUS and OsPIN5b:GUS. Moreover, the transcript levels of the YUCCA2 and ASA2, IAA biosynthetic genes were also monitored in Cd and/or As exposed wild type seedlings. The results highlight that As and Cd affect cyto-histology and morphology of the roots. In particular, they alter the lateral root primordia organization and development with negative consequences on root system architecture. This is due to a disturbance of IAA biosynthesis and transport, as indicated by the altered expression of both ASA2 and YUCCA2 biosynthetic genes, and AUX1 and PIN5b transporter genes

The reticulons: guardians of the structure and function of the endoplasmic reticulum

The endoplasmic reticulum (ER) consists of the nuclear envelope and a peripheral network of tubules and membrane sheets. The tubules are shaped by a specific class of curvature stabilizing proteins, the reticulons and DP1; however it is still unclear how the sheets are assembled. The ER is the cellular compartment responsible for secretory and membrane protein synthesis. The reducing conditions of ER lead to the intra/inter-chain formation of new disulphide bonds into polypeptides during protein folding assessed by enzymatic or spontaneous reactions. Moreover, ER represents the main intracellular calcium storage site and it plays an important role in calcium signaling that impacts many cellular processes. Accordingly, the maintenance of ER function represents an essential condition for the cell, and ER morphology constitutes an important prerogative of it. Furthermore, it is well known that ER undergoes prominent shape transitions during events such as cell division and differentiation. Thus, maintaining the correct ER structure is an essential feature for cellular physiology. Now, it is known that proper ER-associated proteins play a fundamental role in ER tubules formation. Among these ER-shaping proteins are the reticulons (RTN), which are acquiring a relevant position. In fact, beyond the structural role of reticulons, in very recent years new and deeper functional implications of these proteins are emerging in relation to their involvement in several cellular processes

Experiment Investigating the Connection between Weak Values and Contextuality

Weak value measurements have recently given rise to a large interest for both the possibility of measurement amplification and the chance of further quantum mechanics foundations investigation. In particular, a question emerged about weak values being proof of the incompatibility between Quantum Mechanics and Non-Contextual Hidden Variables Theories (NCHVT). A test to provide a conclusive answer to this question was given in [M. Pusey, Phys. Rev. Lett. 113, 200401 (2014)], where a theorem was derived showing the NCHVT incompatibility with the observation of anomalous weak values under specific conditions. In this paper we realize this proposal, clearly pointing out the strict connection between weak values and the contextual nature of Quantum Mechanics.Comment: 5 pages, 4 figure

MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT

Recent epidemiological data have shown a significant decline in breast cancer mortality over the past 15 years, as a result of screening programs, better education, and the introduction of more effective adjuvant treatments1. However, about 20-30% of the patients eventually relapse while approximately 5-7% of cases present with metastatic disease at diagnosis2. Metastatic breast cancer is still largely incurable: the median survival time is generally in the range of 2 to 4 years3. In the metastatic setting, treatment goals can be quite different depending on patient and tumor characteristics. There are patients for whom the main objective is symptom control to improve or maintain quality of life, cases with life-threatening disease for whom a rapid tumor shrinkage is required, asymptomatic patients with slowly growing disease for whom a prolonged progression-free survival (PFS) duration is the desirable target; finally, some patients can obtain an important survival prolongation and a few of them might be cured4. The selection of treatment depends on several factors, including patient characteristics, aggressiveness of the disease, response to previous therapies, time since last exposure, agents used in the past and cumulative doses. Availability and regulatory approval of various anticancer agents further diversify treatment patterns in different part of the world. A rapidly growing pool of effective treatment options for advanced breast cancer has increased response rates and outcome. First, many new cytotoxic drugs are in development or have recently been approved in this setting, such as ixabepilone, eribulin and nab-paclitaxel. For instance, in the phase III trial EMBRACE, eribulin mesylate improved overall survival (median 13.1 months, 95% CI 11.8-14.3), compared to treatment of physician’s choice (median 10.6 months, CI 9.3-12.5; HR 0.81 95% CI 0.66-0.99, p=0.041), in patient who had received two to five prior chemotherapy regimens, including an anthracycline and a taxane for advanced breast cancer.5 In clinical studies, 3-weekly nab-paclitaxel has been shown to increase both the safety and the efficacy of 3-weekly paclitaxel in patients with advanced breast cancer (median time to progression 23 vs 16.9 weeks, hazard ratio 0.75, p=0.006).6 Weekly nab-paclitaxel produced meaningful results even in taxanes pre-treated patients (ORR 14% and 16% in the 100 and 125 mg/sqm cohorts, respectively; median PFS of 3 and 3.5 months, respectively).7 At the same time, research efforts are directed to implement the pool of targeted therapies, in order to offer more individualized options to breast cancer patients. In fact, the molecular breast cancer subtype is a fundamental determinant of treatment choice both in early and advanced setting. Breast cancer consists of at least three different diseases: hormone-sensitive breast cancer, the human epidermal growth factor receptor (HER2)-positive subtype, and triple-negative disease. Each molecular subtype has distinct biological features and a distinct clinical course: hormone receptor–positive (HR+) disease is generally characterized by a more indolent course, with a long disease-free interval (DFI) and a tendency to relapse in the bone or soft tissues; amplification of the HER-2 gene confers a more aggressive clinical behavior to the HR+ subgroup, with a higher propensity for visceral relapses. Both triple-negative breast cancer and hormone receptor–negative (HR-)/HER-2+ breast cancer are aggressive subtypes, with early visceral or central nervous system metastases. Each molecular subtype requires distinct therapeutic approaches. In HR+ tumors, endocrine manipulation is the cornerstone of therapy. Treatment choice depends on many factors such as menopausal status and disease-free interval. For postmenopausal women many agents are available: non-steroidal and steroidal aromatase inhibitors (AI), tamoxifen and fulvestrant; however no definitive recommendation for the optimal cascade can be given. For premenopausal patients, the data on aromatase inhibitors or fulvestrant are more scanty8. In case of life-threatening and rapidly-growing disease, or in case of failure of various endocrine agents, chemotherapy has to be considered. Yet, recent studies have shown that HR+ positive tumors do also derive benefit from additional targeted agents: data from the BOLERO-2 trial showed an impressive improvement in progression free-survival with the addition of everolimus to exemestane vs exemestane alone as first- or second-line treatment for HR+ advanced breast cancer patients, after failure of a non-steroidal AI in the adjuvant or metastatic setting (median PFS 10.6 vs 4.1 months according to central assessment, HR 0.36;95% CI 0.27-0.47, p<0.001)9. Thus, overcoming endocrine resistance by combined targeting of redundancy pathways will be one of the key issues in the near future. In this context, even the association of trastuzumab or lapatinib to endocrine agents is an important option for HR+/HER2+ patients. Targeting HER2 in HR+ breast cancer has been explored as a means of improving endocrine responsiveness. The randomized phase II TAnDEM trial included 207 patients with known ER+/HER2+ metastatic breast cancer and reported a doubling of progression-free survival with the addition of trastuzumab over anastrozole alone (hazard ratio 0.63; 95% CI, 0.47 to 0.84; median PFS, 4.8 v 2.4 months; p =0016)10. Finally, results from a phase III trial of 1,286 patients with metastatic ER+ breast cancer who were randomized to receive either letrozole alone or letrozole combined with lapatinib have been published. In patients with known ER+/HER2+ tumors (n=219), the addition of lapatinib to letrozole significantly reduced the risk of progression as compared to letrozole alone: median PFS was 8.2 v 3.0 months, respectively (HR 0.71; 95% CI, 0.53 to 0.96; p=0.019)11. In HR-/HER2+ tumors, the incorporation of trastuzumab has substantially reversed the negative prognostic impact of HER-2 overexpression/amplification12. However, due to the approval of trastuzumab as standard adjuvant therapy for early HER2+ breast cancer and the emergency of resistance to this drug, the need of new anti-HER2 agents has emerged, as well as the need to clarify the role of continuing trastuzumab beyond progression, with different cytotoxic agents. Lapatinib, combined with capecitabine, has been approved for the treatment of HER2+ metastatic breast cancer patients, previously treated with trastuzumab. Many other anti-HER2 agents are being developed such as T-DM1, neratinib and pertuzumab. In T-DM1 trastuzumab is conjugated with an antimicrotubule drug maytansinoid. Activation of cytotoxicity of this conjugate requires internalization into the cell after binding to HER2. A single-arm, phase II trial (n = 112 MBC patients whose disease progressed on trastuzumab) showed at a follow-up of ≥12 months a median PFS of 4.6 months (95% CI, 3.9 to 8.6) and an overall response rate of 26%. Hypokalemia, thrombocytopenia, and fatigue were the most common observed adverse events. No dose-limiting cardiotoxicity was reported13. T-DM1 is undergoing further testing in the context of several other studies. An open-label, phase III randomized trial (EMILIA) is comparing single-agent T-DM1 with the combination of capecitabine and lapatinib in patients whose HER2-positive disease has progressed on trastuzumab. In another phase III trial MARIANNE, T-DM1 monotherapy is being compared to trastuzumab plus a taxane. Neratinib/HKI-272 is an oral, irreversible, small molecule inhibitor of EGFR/HER1, HER2, and HER4. In an open-label, phase II study, patients with advanced HER2-positive BC with and without prior trastuzumab treatment received neratinib. The 16-week PFS was 59% for patients with prior trastuzumab (n = 63) and 78% for those without (n = 64); median PFS were 22.3 and 39.6 weeks, respectively. The most frequent AEs were diarrhea, nausea, vomiting, and fatigue. Grade 3 or 4 diarrhea occurred in 30% of patients with prior trastuzumab therapy, leading to neratinib dose reduction in 29% of this cohort14. A phase III randomized study of paclitaxel with either neratinib or trastuzumab in MBC is ongoing, as is a randomized phase II study of neratinib alone versus the combination of capecitabine and lapatinib. Pertuzumab is a first-in-class recombinant, humanized monoclonal antibody that binds to domain II of the HER2 receptor, thus inhibiting HER2 heterodimerization with HER1, HER3, and HER4. Recent data from a randomized phase III trial showed that the combination of trastuzumab, pertuzumab and docetaxel as first-line treatment for HER2+ advanced breast cancer patients, significantly improves progression-free survival, with a gain of 6 months in median progression-free survival, as compared to the combination of trastuzumab and docetaxel (PFS 18.5 vs 12.4 months, HR 0.62; 95% CI, 0.51 to 0.75; P<0.001)15. These results contribute to increase the interest in dual HER2 blockade that derived from early breast cancer trials. In this context, the combination of trastuzumab and lapatinib in trastuzumab-pretreated patients resulted in a more prolonged PFS as compared to lapatinib alone (HR 0.73; 95%CI 0.57-0.93, p=0.008)16. Lastly, chemotherapy is the only available option so far for the triple-negative (TNBC) subtype, which is characterized by the absence of hormone receptors and HER-2 negativity. At this time, there are no targeted agents that are specifically approved for the treatment of this breast cancer subtype. Bevacizumab appears to prolong progression-free survival when added to chemotherapy for patients with TNBC (as it does for those with HR+/HER2- disease), but does not enhance survival17. Moreover, neoadjuvant trials provide conflicting results on the role of bevacizumab for TNBC18,19. Although there was great enthusiasm based on phase II data for the combination of carboplatin, gemcitabine and the PARP-inhibitor iniparib, the phase III results did not support the preliminary data20. A variety of other targeted therapies, including the PI3K inhibitors and a number of agents that inhibit DNA repair are under active investigation. Nowadays, more patients are likely to be diagnosed with oligo-metastatic disease, asymptomatic and in good performance status, due to the use of more sophisticated imaging techniques and the information derived from serum-markers dosage; therefore more selective therapeutic strategies that include a multimodality approach and local therapies are becoming more and more important. A substantial improvement in multimodality treatments, including, but not limited to, stereotactic radiosurgery, percutaneous radiofrequency ablation, and minimally invasive surgery, has increased the chance for disease control in selected patients with limited and indolent metastatic disease. In this context, surgery on primary tumor in case of oligometastatic disease has been suggested to improve survival, but further data are needed and a randomized trial addressing this issue is ongoing. Furthermore, an interesting field of research is the molecular characterization of metastatic disease. Biopsies of recurrent sites are not routinely performed and treatment decision for metastatic disease is mainly based on the receptor status of the primary tumor. However, discordance rates in HR and/or HER2 status between primary and recurrent tumors have been reported in the range of 10% to 35%21. Reasons for discordance may include: test artifacts, tumor heterogeneity, genetic drift during progression, selective pressure of adjuvant therapies. Nevertheless, recent reports suggest that the change in the receptor status during tumor progression may have also a prognostic impact22. It is therefore critical to incorporate all disease and patient information to assure the best treatment strategy for a given patient. The choice of the best treatment for metastatic disease has become even more difficult because the more efficacious agents have been progressively incorporated into the management of earlier stages. As a consequence, even if the number of patients who experience disease recurrence is gradually decreasing, treatment options for recurring patients are more and more influenced by prior exposure to adjuvant therapy. Unfortunately, most trials conducted in advanced breast cancer do not take into account all these factors that are necessary for an appropriate decision-making process. A deeper insight into tumor biology and mechanisms of resistance to established therapies will allow to develop new cytotoxic or targeted drugs or new combinations of available drugs for the treatment of metastatic disease. Key preclinical studies are needed, in order to guide the choice of which combination or single-agent deserve to be tested in early phase clinical trials. Moreover, well-designed trials that take into account the critical issues that frequently present in clinical routine are needed, in order to allow for a better translation of scientific results into daily practice

Quantum state reconstruction using binary data from on/off photodetection

The knowledge of the density matrix of a quantum state plays a fundamental role in several fields ranging from quantum information processing to experiments on foundations of quantum mechanics and quantum optics. Recently, a method has been suggested and implemented in order to obtain the reconstruction of the diagonal elements of the density matrix exploiting the information achievable with realistic on/off detectors, e.g. silicon avalanche photo-diodes, only able to discriminate the presence or the absence of light. The purpose of this paper is to provide an overview of the theoretical and experimental developments of the on/off method, including its extension to the reconstruction of the whole density matrix.Comment: revised version, 11 pages, 6 figures, to appear as a review paper on Adv. Science Let

Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: A case report

The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib

Positive Operator-Valued Measure reconstruction of a beam-splitter tree based photon-number-resolving detector

Here we present a reconstruction of the Positive Operator-Value Measurement of a photon-number-resolving detector comprised of three 50:50 beamsplitters in a tree configuration, terminated with four single-photon avalanche detectors. The four detectors' outputs are processed by an electronic board that discriminates detected photon number states from 0 to 4 and implements a "smart counting" routine to compensate for dead time issues at high count rates